Effects of NO-1886 on inflammation-associated cytokines in high-fat/high-sucrose/high-cholesterol diet-fed miniature pigs.
Inflammation, closely associated with obesity, is emerging as an important risk factor for the pathophysiological development of atherosclerosis and diabetes mellitus. Fat balance is critical in the aetiology of obesity. Lipoprotein lipase is an important enzyme in lipid metabolism. The aim of this study was to investigate the long-term effect of the lipoprotein lipase activator, NO-1886, on inflammation cytokines, adiposity and related diseases in miniature pigs fed a high-fat/high-sucrose/high-cholesterol diet (HFSC diet). Chinese Bama-miniature pigs were fed a control diet or HFSC diet with or without NO-1886 for 5 months. The levels of inflammation-associated cytokines were determined using the antibody arrays. Feeding of the HFSC diet to miniature pigs markedly increased the expression of inflammatory cytokines. On the other hand, supplementation of NO-1886 to HFSC diet decreased the expression of inflammatory cytokines significantly, protecting against the development of atherosclerosis and diabetes mellitus. NO-1886 may have a beneficial effect on the most inflammation-associated cytokines, and this effect may contribute to improving atherosclerosis and diabetes mellitus.
Cai
Manbo
M
Institute of Cardiovascular Research, Nanhua University, Hengyang, Hunan, China.
Yin
Weidong
W
Li
Qinkai
Q
Liao
Duanfang
D
Tsutsumi
Kazuhiko
K
Hou
Hongjie
H
Liu
Yi
Y
Zhang
Chi
C
Li
Jianjun
J
Wang
Zongbao
Z
Xiao
Junxia
J
D000818:Animals; D050197:Atherosclerosis / Q000097:blood / Q000378:metabolism / Q000517:prevention & control; D001549:Benzamides / Q000494:pharmacology*; D002791:Cholesterol, Dietary / Q000008:administration & dosage*; D016207:Cytokines / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000097:blood / Q000378:metabolism / Q000517:prevention & control; D004040:Dietary Carbohydrates / Q000008:administration & dosage*; D004041:Dietary Fats / Q000008:administration & dosage*; D005951:Glucose Tolerance Test; D000960:Hypolipidemic Agents / Q000494:pharmacology; D007249:Inflammation / Q000378:metabolism; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008297:Male; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D013395:Sucrose / Q000008:administration & dosage; D013552:Swine; D013556:Swine, Miniature; D017539:Tunica Intima / Q000187:drug effects / Q000378:metabolism / Q000473:pathology
D001549:Benzamides; D002791:Cholesterol, Dietary; D016207:Cytokines; D004040:Dietary Carbohydrates; D004041:Dietary Fats; D000960:Hypolipidemic Agents; D007328:Insulin; D008055:Lipids; D009943:Organophosphorus Compounds; C082137:4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide; D013395:Sucrose